Search Results 301-310 of 680 for ⚕보증사이트 【위너보증.com / 가입코드 9122】 정품슬롯 ⚕

  1. Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Relapsed/Refractory Multiple Myeloma - Mayo Clinic

    Ixazomib may stop the growth of cancer by interfering with proteasomes (the protein breakdown mechanism in the cells). Pomalidomide and dexamethasone can modify ...

  2. A Study to Evaluate the Effectiveness of Acetazolamide to Treat Patients with Ataxia in PMM2-Congenital Disorder of Glycosylation - Mayo Clinic

    The purpose of this study is to evaluate acetazolamide for the treatment of ataxia in patients with PMM2-CDG. Participation eligibility. Participant eligibility ...

  3. Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma - Mayo Clinic

    Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer cells might ...

  4. Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study - Mayo Clinic

    The purpose of this study is to determine whether the addition of stereotactic ablative radiotherapy (SABR) to the primary tumor in combination with ...

  5. A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  6. Nilotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia - Mayo Clinic

    About this study. In this study researchers want to find out more about the side effects of a new drug for Philadelphia chromosome-positive (Ph+) acute ...

  7. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  8. A Study to Evaluate the Effectiveness and Safety of Risankizumab in Subjects with Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to ...

  9. A Study to Evaluate Tazemetostat and Pembrolizumab to Treat Advanced Urothelial Carcinoma - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  10. A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Mayo Clinic

    MOR00208 is an investigational drug. RTX and BEN are both approved in many countries for the treatment of lymphomas. The combination of both is considered and ...